Skip to main content
. 2019 Apr 28;11(5):596. doi: 10.3390/cancers11050596

Figure 2.

Figure 2

Serum levels of OPN, MIF anti-IL-8 autoantibody and CA125 are elevated in the validation set from ovarian cancer patients and healthy controls. (A) OPN antigen; (B) MIF antigen; (C) anti-IL-8 autoantibody and (D) CA125 antigen. In the upper panels, each symbol represents the average of duplicate serum samples from individual early stage ovarian cancer cases (green), late stage ovarian cancer cases (red) or controls (blue). The middle panels contain a scatter plot where the blue line represents the median value in early and late stage case and control groups, respectively. The red dashed lines in each plot represent the cut-off value at 98% specificity for OPN, MIF and anti-IL-8 AAb, and cut-off value of 35 U/mL for CA125. The lower panel is a table displaying the sensitivity for early and late stage ovarian cancer cases and controls near 98% specificity.